C M Lindley

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis
    C Lindley
    School of Pharmacy, University of North Carolina, Chapel Hill 27599, USA
    Am J Health Syst Pharm 57:1685-97. 2000
  2. ncbi request reprint The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes
    Celeste Lindley
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Drug Metab Dispos 30:814-22. 2002
  3. ncbi request reprint Coagulation products and their uses
    S S Shord
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill 27599 7360, USA
    Am J Health Syst Pharm 57:1403-17; quiz 1418-20. 2000
  4. ncbi request reprint Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone
    Celeste Lindley
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    Am J Clin Oncol 28:270-6. 2005
  5. ncbi request reprint Phase I study of a novel recombinant human soluble thrombomodulin, ART-123
    S Moll
    University of North Carolina School of Medicine, Department of Medicine, Division of Hematology Oncology, Chapel Hill, NC 27599, USA
    J Thromb Haemost 2:1745-51. 2004
  6. ncbi request reprint Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer
    C Lindley
    School of Pharmacy and Medicine, University of North Carolina at Chapel Hill, 27599 7360, USA
    J Clin Oncol 16:1380-7. 1998
  7. ncbi request reprint Documentation of pain assessment and treatment: how are we doing?
    J A Dalton
    School of Nursing, CB 7460, Carrington Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Pain Manag Nurs 2:54-64. 2001
  8. ncbi request reprint Anagrelide: a novel agent for the treatment of myeloproliferative disorders
    S L Pescatore
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, Beard Hall CB 7360, Chapel Hill, NC 27514, USA
    Expert Opin Pharmacother 1:537-46. 2000
  9. ncbi request reprint Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study
    J S McCune
    School of Pharmacy, University of Washington, Seattle, WA, USA
    Ann Pharmacother 35:14-20. 2001
  10. ncbi request reprint Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation
    S R Faucette
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA
    Drug Metab Dispos 29:1123-9. 2001

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis
    C Lindley
    School of Pharmacy, University of North Carolina, Chapel Hill 27599, USA
    Am J Health Syst Pharm 57:1685-97. 2000
    ..Oral dolasetron 100 or 200 mg once daily also prevented emesis. Oral administration of 5-HT3-receptor antagonists for the prevention of acute emesis associated with chemotherapy is rational and appears to be effective...
  2. ncbi request reprint The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes
    Celeste Lindley
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Drug Metab Dispos 30:814-22. 2002
    ..The impact of these effects on the efficacy and toxicity of CPA therapy warrants further investigation...
  3. ncbi request reprint Coagulation products and their uses
    S S Shord
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill 27599 7360, USA
    Am J Health Syst Pharm 57:1403-17; quiz 1418-20. 2000
    ..A thorough understanding of each coagulation product can guide product selection, dosing, and treatment duration and can reduce the risk of viral transmission...
  4. ncbi request reprint Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone
    Celeste Lindley
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    Am J Clin Oncol 28:270-6. 2005
    ....
  5. ncbi request reprint Phase I study of a novel recombinant human soluble thrombomodulin, ART-123
    S Moll
    University of North Carolina School of Medicine, Department of Medicine, Division of Hematology Oncology, Chapel Hill, NC 27599, USA
    J Thromb Haemost 2:1745-51. 2004
    ..Recombinant human thrombomodulin is a novel anticoagulant with a long half-life in animal models...
  6. ncbi request reprint Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer
    C Lindley
    School of Pharmacy and Medicine, University of North Carolina at Chapel Hill, 27599 7360, USA
    J Clin Oncol 16:1380-7. 1998
    ....
  7. ncbi request reprint Documentation of pain assessment and treatment: how are we doing?
    J A Dalton
    School of Nursing, CB 7460, Carrington Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Pain Manag Nurs 2:54-64. 2001
    ..More documentation of patient pain history, clinical problems, treatment, and follow-up action is needed to improve practice and research...
  8. ncbi request reprint Anagrelide: a novel agent for the treatment of myeloproliferative disorders
    S L Pescatore
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, Beard Hall CB 7360, Chapel Hill, NC 27514, USA
    Expert Opin Pharmacother 1:537-46. 2000
    ..Anagrelide 2 mg/day for one year costs approximately US$6439, and treatment must continue indefinitely [1]...
  9. ncbi request reprint Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study
    J S McCune
    School of Pharmacy, University of Washington, Seattle, WA, USA
    Ann Pharmacother 35:14-20. 2001
    ..Guideline revision and outcome documentation by the oncology pharmacists resulted in increased compliance with institution guidelines and a 40% cost savings...
  10. ncbi request reprint Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation
    S R Faucette
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA
    Drug Metab Dispos 29:1123-9. 2001
    ..These results suggest that CYP3A4 does not significantly catalyze BUP hydroxylation. Furthermore, these results complement recent data supporting selectivity of BUP hydroxylation for CYP2B6 at 500 microM BUP...
  11. ncbi request reprint Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing
    A Donahue
    University of North Carolina, University of Washington, CB #7360, Beard Hall, Box 357630, Chapel Hill, NC 27599-7360 Seattle, WA 98195, USA
    Cancer Chemother Pharmacol 47:373-9. 2001
    ..The greater negative bias found for the latter three estimates of carboplatin clearance could result in underdosing of carboplatin...
  12. ncbi request reprint Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route
    Andrew Finn
    BDSI, Inc, 2501 Aerial Center Parkway, Suite 205, Morrisville, NC 27560, USA
    J Clin Pharmacol 45:1383-90. 2005
    ..Buccal administration of prochlorperazine, twice daily, should enhance the therapeutic role of prochlorperazine in preventing and treating nausea and vomiting...
  13. ncbi request reprint Pemetrexed: a multitargeted antifolate
    Kristan D Rollins
    Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina School of Pharmacy, Chapel Hill, NC 27599 7360, USA
    Clin Ther 27:1343-82. 2005
    ..Pemetrexed is the first agent approved for the treatment of MPM. In August 2004, pemetrexed was approved as a second-line, single-agent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)...
  14. ncbi request reprint A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  15. ncbi request reprint Capecitabine: a review
    Christine M Walko
    Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina School of Pharmacy, Chapel Hill, North Carolina 27599 7360, USA
    Clin Ther 27:23-44. 2005
    ..Capecitabine was developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentrations through tumor-specific conversion to the active drug...
  16. ncbi request reprint Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy
    Celeste Lindley
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Anticancer Drugs 15:453-9. 2004
    ..However, significant intraindividual variability exists in the apparent oral clearance of busulfan and follow-up therapeutic drug monitoring is recommended particularly if the desired target AUC range is narrow...
  17. ncbi request reprint Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers
    Stephanie R Faucette
    Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    Drug Metab Dispos 32:348-58. 2004
    ..These results indicate that CYP2B6 is highly inducible by known CYP3A4 inducers and suggest that hPXR is a major determinant of CYP2B6-inducible expression for many, but not all, compounds evaluated in this study...
  18. ncbi request reprint Aprepitant--a novel NK1-receptor antagonist
    Lisa Patel
    Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Expert Opin Pharmacother 4:2279-96. 2003
    ..The following review provides an overview of aprepitant including pharmacokinetics, pharmacology and clinical evidence for its use in CINV. A brief discussion of other possible indications for aprepitant will also be presented...
  19. ncbi request reprint Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy
    Imad Treish
    University of North Carolina Hospitals, Manning Drive, Chapel Hill, NC 27514, USA
    Support Care Cancer 11:516-21. 2003
    ..Our goal was to evaluate the efficacy and tolerability of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy...
  20. ncbi request reprint Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
    ..We designed this pharmacokinetic study to assess the ability of a fixed dose rate of gemcitabine to achieve the desired steady-state concentration in the absence and presence of paclitaxel in patients with solid tumors...
  21. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  22. ncbi request reprint Use of NSAIDs for the chemoprevention of colorectal cancer
    Jill M Herendeen
    University of North Carolina School of Pharmacy, Chapel Hill, NC, USA
    Ann Pharmacother 37:1664-74. 2003
    ..To discuss the role of nonsteroidal antiinflammatory drugs (NSAIDs) in the chemoprevention of colorectal cancer...
  23. ncbi request reprint Is patient satisfaction a legitimate outcome of pain management?
    John Carlson
    School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7460, USA
    J Pain Symptom Manage 25:264-75. 2003
    ..Pain severity ratings near the time satisfaction was measured were more influential than earlier ratings...
  24. ncbi request reprint Developments in breast cancer therapy
    Celeste Lindley
    University of North Carolina School of Pharmacy, Chapel Hill, USA
    J Am Pharm Assoc (Wash) 42:S30-1. 2002
    ..The aromatase inhibitors are now considered first-line therapy in metastatic disease, and use of the monoclonal antibody trastuzumab has increased 5-year survival rates...
  25. ncbi request reprint Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity
    Stacy S Shord
    School of Pharmacy, University of North Carolina at Chapel Hill, 27599, USA
    Anticancer Res 22:2301-9. 2002
    ..This study was conducted to characterize the pharmacokinetic parameters of oxaliplatin and Pt(dach)Cl2 and to determine the extent to which oxaliplatin undergoes biotransformation to Pt(dach)Cl2 in humans...
  26. ncbi request reprint Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies
    Ted Shih
    Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina School of Pharmacy, Chapel Hill, USA
    Clin Ther 28:1779-802. 2006
    ....